EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2

Koen Van Laere, Andrea Varrone, Jan Booij, Thierry Vander Borght, Flavio Nobili, Özlem L. Kapucu, Zuzana Walker, Kjell Någren, Klaus Tatsch, Jacques Darcourt

Research output: Contribution to journalReview article

Abstract

The guidelines summarize the current views of the European Association of Nuclear Medicine Neuroimaging Committee (ENC). The aims of the guidelines are to assist nuclear medicine practitioners in making recommendations, performing, interpreting and reporting the results of clinical dopamine D2 receptor SPECT or PET studies, and to achieve a high quality standard of dopamine D2 receptor imaging, which will increase the impact of this technique in neurological practice. The present document is an update of the first guidelines for SPECT using D2 receptor ligands labelled with 123I [1] and was guided by the views of the Society of Nuclear Medicine Brain Imaging Council [2], and the individual experience of experts in European countries. The guidelines intend to present information specifically adapted to European practice. The information provided should be taken in the context of local conditions and regulations.

Original languageEnglish
Pages (from-to)434-442
Number of pages9
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume37
Issue number2
DOIs
Publication statusPublished - Feb 1 2010

Keywords

  • Brain
  • D2 receptor
  • Dopamine
  • Parkinsonism
  • PET
  • SPECT

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2'. Together they form a unique fingerprint.

  • Cite this

    Van Laere, K., Varrone, A., Booij, J., Vander Borght, T., Nobili, F., Kapucu, Ö. L., Walker, Z., Någren, K., Tatsch, K., & Darcourt, J. (2010). EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2. European Journal of Nuclear Medicine and Molecular Imaging, 37(2), 434-442. https://doi.org/10.1007/s00259-009-1265-z